A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

NCT04666740 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma
Homologous Recombination Deficiency (HRD)

Interventions

DRUG: Pembrolizumab
DRUG: Olaparib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]